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Abstract
Background: Enzymatic modification of  aminoglycosides is the primary mechanism of  resistance by Pseudomonas aerug-
inosa. 
Obejectives: We investigated the occurrence and mechanism of  aminoglycosides resistance in P. aeruginosa isolates from 
hospitals in SouthWest Nigeria. 
Methods: A total of  54 consecutive, non-duplicate clinical isolates of  P. aeruginosa were studied for the presence of  amino-
glycosides -modifying enzymes (AMEs) by PCR amplification and sequencing of  genes encoding AMEs. 
Results and conclusion: Two types of  AME genes [aac (6′) – I and ant (2′′) – I] were found in 12 isolates out of  54. Seven 
strains harboured one or more types of  enzymes of  which aac (6′) – I was the most frequently found gene (10/54 isolates, 
18.5%). None of  the isolates investigated in this study were positive for aph, aac (3) and aac (6′′) – II genes. Prevalence of  P. 
aeruginosa producing AME genes in this study may suggest aminoglycosides use in Nigeria. This study highlights need for 
functional antimicrobial surveillance system in Nigeria.
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Introduction
Pseudomonas aeruginosa is an adaptable Gram-neg-
ative rod-shaped bacterium found almost everywhere 
especially in moist places. It is an opportunistic hu-
man pathogen implicated in more hospital-acquired 
infections than community-acquired ones1. According 
to several scientific reports, P. aeruginosa is the main 
cause of  ventilator-associated pneumonia, burn infec-
tions, and infections in cystic fibrosis patients2-4. This 
pathogen has been involved in several nosocomial in-
fections such as bacteremia, urinary tract infections 
and endocarditis5. Treatment options for established 
Pseudomonal infections are always a difficult task due 
to its problematic multidrug resistance traits6. Antibi-
otic resistance characteristics in P. aeruginosa are both 
chromosomal and acquired or by horizontal transfer 
of  resistance determinant often carried within plas-
mids and integrons7. Prescriptions for antipseudomon-
al drugs are combination therapy for effective synergy 
preventing the development of  resistance in the course 
of  treatments1. 
Aminoglycosides are good antipseudomonal agents ad-
ministered in combination therapy with β-lactams drugs 
1,8. P. aeruginosa resistance to aminoglycosides arises via 
enzymatic modification of  the aminoglycosides by plas-
mid-or chromosome-encoded aminoglycosides -modi-
fying enzymes (AMEs), impermeability, multidrug-ac-
tive efflux systems and 16S rRNA methylase genes9-11. 
Of  these mechanisms, the enzymatic modification of  
aminoglycosides by plasmid or chromosome encoded 
genes is a more prevalent mechanism found in P. aerug-
inosa8. These modifying enzymes, aminoglycoside acet-
yltransferase (AAC), nucleotidyltransferase (ANT) and 
phosphotransferase (APH) are of  clinical significance 
because their substrates includes the most important 
African Health Sciences Vol 15 Issue 4, December 20151277
antipseudomonal aminoglycosides that are commonly 
prescribed8. Spread of  such genes especially in the hos-
pital environment can further complicate treatments of  
infected individuals, hence a constant study and moni-
toring of  resistance rate and patterns, of  clinically im-
portant pathogens in our environment is of  great signif-
icance. Information regarding the prevalence of  these 
enzymes among clinical isolates of  pathogenic bacteria 
are currently lacking in our region. Since amikacin and 
gentamicin are the most commonly prescribed amino-
glycosides among antipseudomonas drugs in Nigeria, 
it is essential to carry out an investigation on the pres-
ence of  these resistance genes among isolated strains 
of  resistant P. aeruginosa in our hospitals. In this study, 
we reported the first detection of  aac(6′)-I and ant(2′′)-I 
AMEs from clinical isolates of  multidrug resistant P. 
aeruginosa from SouthWest Nigeria.   
 
Materials and method
Bacterial isolates and antimicrobial susceptibility
Fifty-four consecutive non-duplicated P. aerugino-
sa strains were collected from 5 hospitals (University 
College Hospital UCH, Catholic Hospital Oluyoro, 
Catholic Hospital Eleta , Federal Medical Centre Akure, 
Federal Medical Centre Abeokuta, 5– 20 isolates per 
centre) in SouthWest States of  Nigeria between March 
to September 2010. Isolates were from different clinical 
samples (urine, wound swab, pus, ear swab, blood and 
vagina swab etc.). All the isolates were collected under 
approved ethical standards and verified using standard 
biochemical methods as described previously12. An-
timicrobial susceptibility testing (AST) against amika-
cin, gentamicin, carbenicillin, piperacillin, ceftazidime, 
cefotaxime, ceftriaxone, ciprofloxacin (HiMedia India), 
was performed by disc diffusion technique and inter-
preted according to the Clinical and Laboratory Stand-
ards Institute guidelines13. The Etest (HiMedia India) 
technique for the determination of  minimum inhibi-
tory concentration (MIC) was carried out according to 
the manufacturer’s instructions. For quality control of  
the experiment P. aeruginosa ATCC 27853 and E.coli 
ATCC 25922 were used.
PCR amplification
The DNA template obtained from the supernatant of  a 
boiled extracts of  P. aeruginosa cells was used for PCR 
amplification as described previously14,15. PCR amplifi-
cation was carried out in a volume of  25µl containing 
the following: 1 – 2 µl DNA templates, 20pM of  each 
primer, 250 µM of  dNTP, 10mM Tris-HCl (pH8.3), 
50mM KCl, 2.5mM MgCl2 and 1.5U of  Taq DNA pol-
ymerase (Promega Corporation, Madison, USA), using 
various annealing conditions for each primer set for the 
detection of  various AME genes (aac(3)-I, aac(3)-II, 
aac(6′)-I, aac(6′)-II, ant(2′′)-I and aph(3′)-VI) 15 investi-
gated in this study. 
Statistical analysis
Statistical analysis was carried out using Statistical Pack-
age for Social Sciences (SPSS) software (version 11.5) 
for Windows (x2-test). A P value of  0.05 was considered 
significant.
Results
Highest number of  P. aeruginosa isolates was from 
urine (38.9%) followed by wound (20.4%), pus (11.1%) 
and ear swab (9.3%), while 5.6%, 5.5%, 3.7%, 3.7% and 
1.8% isolates were from throat swab, blood, tracheal as-
pirate, HVS and leg ulcer respectively. Susceptibilities 
of  the isolates and MIC ranges are summarized in Table 
1. 
Table 1. Susceptibility of AME positive isolates to various antimicrobial agents  
  
Agent/µg Percentage resistance Percentage susceptibility MIC range (ug/ml) 
Amikacin /30 41.66 58.33 ≤ 0.1 – >256 
Gentamicin/10 83.33 16.66      >256 
Carbenicillin/100 83.33 16.66 ≤ 5.0 – >240 
Piperacillin/100 75.00 25.00 ≤ 5.0 – >240 
Ceftazidime/30 25.00 75.00 ≤ 5.0 – ≥240 
Cefotaxime/30 91.66 8.33 ≤ 3.0 – >15.0 
Ceftriaxone/30 100.00 0      >240 
Ciprofloxacin/5 66.66 33.33 ≤ 0.25 – >240 
Levofloxacin/5 58.33 41.66 ≤ 0.25 – >240 
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Highest resistance was observed for ceftriaxone 
(100%), cefotaxime (91.66%), followed by carbenicillin 
(83.33%), gentamicin (83.33%), piperacillin (75.00%) 
and moderately to ciprofloxacin (66.66%), levofloxacin 
(58.33%), amikacin (41.66%) and ceftazidime (25%). 
Resistance among the isolates was distributed across 
the hospitals.
The relationship between AME positive isolates sourc-
es and distributions are represented in Table 2. 
Table 2. Relationships between isolates sources, distributions  
and their respective AME genes 
 
Strain I.D Source Patient 
Age/sex 
Hospital         AMEs detected 
aac (6′)-I      aac (6′)-I      
ODM 5 Pus 28   Male Eleta + + 
ODM 8 Wound  35   Female UCH + + 
ODM 17 Urine 28   Female Eleta + + 
ODM 24 Urine 26   Male Oluyoro + + 
ODM 25 Urine 21   Female UCH + — 
ODM 32 Wound  32   Female UCH + + 
ODM 34 Vaginal  30   Female FMC  + + 
ODM 38 Urine 29   Female Oluyoro + + 
ODM 40 Vaginal  30   Female UCH + — 
ODM 45 Wound  38   Female Oluyoro — + 
ODM 48 Urine 43   Male Oluyoro + — 
ODM 49 Urine 12   Male UCH — + 
The PCR result gave two types of  AME genes aac (6′) 
– I and ant (2′′) – I in 12 (22.2%) out of  the 54 isolates 
investigated and aac (6′) – I was the most frequently 
found gene in 10 (18.5%) isolates. Seven (12.9%) iso-
lates harboured both aac (6′) – I and ant (2′′) – I genes 
(Table 3). None of  the isolates investigated in this study 
were positive for aph, aac (3) and aac (6′′) – II genes. 
The aac (6′) – I and ant (2′′) – I genes had statistical-
ly significant association with amikacin and gentamicin 
resistance individually (x2 test, p≤0.02), while suscepti-
bility was retained in the presence of  at least one AME 
gene in 3 isolate. 
Table 3. Prevalence of AMEs and correlation between antibiograms and AME genes in 
aminoglycoside resistant P. aeruginosa isolates 
  






Observed result of aminoglycosides resistance 
phenotypes (no of isolates) 
aac (6’)-1 10(18.5) AMK Unexpected resistance to GEN (3) 
As expected (7) 
ant(2’’)-1 9(16.6) GEN Unexpected resistance to AMK(1) 
As expected (8) 
aac(6’)-I +ant(2”)-I 7(12.9) AMK, GEN Unexpected susceptibility to AMK (1) 
Unexpected susceptibility to GEN (1) 
Unexpected susceptibility to AMK+ GEN (1) 
As expected (4) 
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Discussion 
Aminoglycosides is a class of  antibiotics with wide 
acceptance because of  their stability against many re-
sistant bacteria16. This study describes the carriage of  
AMEs among multidrug resistant clinical isolates of  
P. aeruginosa. The frequency of  AME genes detected 
from clinical isolates of  P. aeruginosa from different 
countries varies. The 22.2% incidence rate of  AME 
genes observed in this study is lower than previously 
reported rate of  80% from Greece 17, 87.3% from Ko-
rea15, 43.5% from India18, and 54% from Iran19. Out 
of  the three classes of  AMES (aph, aac and ant) inves-
tigated in this study, only aac(6′)-I and ant(2′′)-I genes 
were detected while aac (6′) – I was the most frequent. 
This is in line with previous studies conducted in Bel-
gium, Greece, France and India, where aac(6′)-I was 
the most frequently detected AME genes9,18,20 but is in 
sharp contrast to studies conducted in USA, Korea and 
Iran where the most common AME gene detected were 
aac(6′)-II  and aph (3′)-IV9,15,19. It has been previously 
reported that the occurrence of  these combination 
of  enzymes varied by geographic regions and among 
hospitals9, this suggests a reason for differences in our 
result and other findings. Consistent with other previ-
ous studies that reported co-habitation of  one or more 
AME genes in a single P. aeruginosa isolates9,15,19, 12.9% 
of  P. aeruginosa isolates in this study harbours both 
aac(6′)-I and ant(2′′)-I genes and they were distributed 
among the selected hospitals (Table 1). 
According to previous reports8,20,21, the presence of  
aac(6′)-I gene in an organism is significant for amikacin 
resistance while ant(2′′)-I  is responsible for the inacti-
vation of  gentamicin. However, in this present study 
we observed unexpected resistance phenotypes in some 
of  the isolates that is contrary to our antimicrobial sus-
ceptibility test (AST) and PCR amplification of  AMEs 
results. For instance 3 of  the isolates harbouring aac 
(6′)-I gene which has been reported to have amikacin as 
a substrate showed resistance to gentamicin while one 
isolate showed susceptibility to both drugs in spite of  
the presence of  both AME genes. We couldn’t identify 
the reason for the latter but we believe the presence 
of  undetectable genes located at the integrons of  these 
isolates as was reported in our previous study14 or other 
resistance mechanisms such as efflux pumps might be 
the reasons for the former. Similar observations have 
also been reported from other studies15,19, where sev-
eral AME PCR results did not correlate with the AST. 
Detection of  AMEs is a useful tool especially among 
clinical isolates because the genes for the aminoglyco-
side-modifying enzymes are transferable and are often 
located on plasmids or transposons along with genes en-
coding resistance to other classes of  antibacterials. Our 
study has not identified the transferability of  the AME 
genes among isolates or the spread of  few strains carry-
ing these genes, this however requires further investiga-
tion. Unabated spread of  AMEs in developed countries 
due to the use of  aminoglycoside has been a clinical 
challenge for over two decades; however, incidence of  
these genes in Nigeria is highly disturbing because there 
are no functional antimicrobial resistance surveillance 
programmes available in Nigeria. Data on the amino-
glycoside mechanisms of  resistance by P. aeruginosa in 
Nigeria is currently lacking. To our knowledge, this is 
the first report of  detection of  AMEs genes in clinical 
P. aeruginosa isolates from Nigeria. 
Conclusion
In summary, this study reports 22.2% P. aeruginosa 
isolates harbouring aac(6′)-I and ant(2′′)-I AMEs genes 
from the investigated hospitals in SouthWestern Ni-
geria. Considering the fact that aminoglycosides are 
good antipseudomonal prescribed for the treatments 
of  Pseudomonal infections, unabated spread of  AME 
genes especially in our region is worrisome .Constant 
monitoring of  aminoglycosides modifying genes is nec-
essary considering their co-selection and easy dissem-
ination among multidrug resistant bacteria. A call for 
a functional antimicrobial resistance surveillance pro-
gramme in Nigeria is of  necessity. 
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